Citation Impact
Citing Papers
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro
2006 StandoutNobel
Cyclic GMP-AMP Is an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA
2012 StandoutScience
Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program
2007 StandoutNobel
MicroRNA-155 is induced during the macrophage inflammatory response
2007 StandoutNobel
Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes
2009
Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
2010
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity
2004 StandoutNobel
Review: IFN- α / β Receptor Interactions to Biologic Outcomes: Understanding the Circuitry
2002
Innate Immunity in Pluripotent Human Cells
2013
Specificity of signaling by STAT1 depends on SH2 and C-terminal domains that regulate Ser727 phosphorylation, differentially affecting specific target gene expression
2001
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
2001 StandoutNature
Mechanisms of type-I- and type-II-interferon-mediated signalling
2005 Standout
Cellular and Gene Expression Responses Involved in the Rapid Growth Inhibition of Human Cancer Cells by RNA Interference-mediated Depletion of Telomerase RNA
2005 StandoutNobel
DIM stimulates IFNγ gene expression in human breast cancer cells via the specific activation of JNK and p38 pathways
2005
Retinoic acid receptors: From molecular mechanisms to cancer therapy
2014
Oncogenic kinase signalling
2001 StandoutNature
Epigenetics in human disease and prospects for epigenetic therapy
2004 StandoutNature
Drug discovery approaches targeting the PI3K/Akt pathway in cancer
2008
Human ADAR1 Prevents Endogenous RNA from Triggering Translational Shutdown
2018 StandoutNobel
TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity
2007 StandoutNobel
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
2000
miRTarBase update 2014: an information resource for experimentally validated miRNA-target interactions
2013
Stat3 as an Oncogene
1999 Standout
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
2001 StandoutNature
Rosiglitazone and Retinoic Acid Induce Uncoupling Protein-1 (UCP-1) in a p38 Mitogen-activated Protein Kinase-dependent Manner in Fetal Primary Brown Adipocytes
2002
The multilayered complexity of ceRNA crosstalk and competition
2014 StandoutNature
The Epigenomics of Cancer
2007 Standout
Inhibitor of κB Kinase ϵ (IKKϵ), STAT1, and IFIT2 Proteins Define Novel Innate Immune Effector Pathway against West Nile Virus Infection
2011
Antitumour actions of interferons: implications for cancer therapy
2016
Serine phosphorylation of STATs
2000
Structural and functional features of central nervous system lymphatic vessels
2015 StandoutNature
A Long Noncoding RNA Controls Muscle Differentiation by Functioning as a Competing Endogenous RNA
2011 Standout
miRNA–target chimeras reveal miRNA 3′-end pairing as a major determinant of Argonaute target specificity
2015 StandoutNobel
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
2003
Intrinsic Immunity Shapes Viral Resistance of Stem Cells
2017 StandoutNobel
Natural RNA circles function as efficient microRNA sponges
2013 StandoutNature
STATs in oncogenesis
2000 Standout
Activation of STAT transcription factors in oncogenic tyrosine kinase signaling
1998
Interferon signalling network in innate defence
2006
IFNβ-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage
2013 StandoutNobel
The IFN-λ-IFN-λR1-IL-10Rβ Complex Reveals Structural Features Underlying Type III IFN Functional Plasticity
2017 StandoutNobel
Reactivating the expression of methylation silenced genes in human cancer
2002
Free radicals and antioxidants in normal physiological functions and human disease
2006 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
2017
Anatomic and functional evaluation of the lymphatics and lymph nodes in diagnosis of lymphatic circulation disorders with contrast magnetic resonance lymphangiography
2009
A diverse range of gene products are effectors of the type I interferon antiviral response
2011 StandoutNatureNobel
Cell-type and Donor-specific Transcriptional Responses to Interferon-α
2002
Immunomodulatory functions of type I interferons
2012
Stat1-dependent and -independent pathways in IFN-γ-dependent signaling
2002
What We Talk About When We Talk About Fat
2014 Standout
The Noncoding RNA Revolution—Trashing Old Rules to Forge New Ones
2014 Standout
Interferons α and λ Inhibit Hepatitis C Virus Replication With Distinct Signal Transduction and Gene Regulation Kinetics
2006 StandoutNobel
Senescence is an endogenous trigger for microRNA-directed transcriptional gene silencing in human cells
2012
Cytokine Signaling in 2002
2002 Standout
Understanding and altering cell tropism of vesicular stomatitis virus
2013
The molecular characterization and clinical management of multiple myeloma in the post-genome era
2009
The PI3K Pathway in Human Disease
2017 Standout
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
2011 StandoutNobel
Fyn and JAK2 Mediate Ras Activation by Reactive Oxygen Species
1999
Treatment of Multiple Myeloma: A Comprehensive Review
2009
Regulatory Effects of Mammalian Target of Rapamycin-activated Pathways in Type I and II Interferon Signaling
2006
Magnetically Triggered Dual Functional Nanoparticles for Resistance‐Free Apoptotic Hyperthermia
2013
Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma
2010
Complex Modulation of Cell Type-Specific Signaling in Response to Type I Interferons
2006
Vitamin A and retinoid signaling: genomic and nongenomic effects
2013
starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein–RNA interaction networks from large-scale CLIP-Seq data
2013 Standout
An Extensive MicroRNA-Mediated Network of RNA-RNA Interactions Regulates Established Oncogenic Pathways in Glioblastoma
2011
Interferon-Dependent Engagement of Eukaryotic Initiation Factor 4B via S6 Kinase (S6K)- and Ribosomal Protein S6K-Mediated Signals
2009
Interferon-gamma inhibits interferon-alpha signalling in hepatic cells: evidence for the involvement of STAT1 induction and hyperexpression of STAT1 in chronic hepatitis C
2004
Structure of the STRA6 receptor for retinol uptake
2016 StandoutScienceNobel
HOW CELLS RESPOND TO INTERFERONS
1998 Standout
2016
Bis- and Trisindolylmethanes (BIMs and TIMs)
2009 Standout
Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
2010
Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study
2010
Differential regulation of the p70 S6 kinase pathway by interferon α (IFNα) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells
2005
Iterative in Situ Click Chemistry Assembles a Branched Capture Agent and Allosteric Inhibitor for Akt1
2011 StandoutNobel
TYPE I INTERFERONS (α/β) IN IMMUNITY AND AUTOIMMUNITY
2004 StandoutNobel
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents
2008
Bis-indols: a novel class of molecules enhancing the cytodifferentiating properties of retinoids in myeloid leukemia cells
2002
Multiple Myeloma
2010
Interferon-Stimulated Genes: A Complex Web of Host Defenses
2014 StandoutNobel
Demystifying the nuclear function of Argonaute proteins
2014
The Two Faces of Interferon-γ in Cancer
2011
Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells
1999
PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells
2003 StandoutNobel
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial
2009
Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays
1998 Standout
RNA Scanning of a Molecular Machine with a Built-in Ruler
2016 StandoutNobel
Type III Interferon (IFN) Induces a Type I IFN-Like Response in a Restricted Subset of Cells through Signaling Pathways Involving both the Jak-STAT Pathway and the Mitogen-Activated Protein Kinases
2007
How I treat multiple myeloma in younger patients
2009
Differential Responses to IFN-α Subtypes in Human T Cells and Dendritic Cells
2003
Multiple Myeloma
2011 Standout
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Free Radicals in the Physiological Control of Cell Function
2002 Standout
Interferon regulatory factor 2 protects mice from lethal viral neuroinvasion
2016 StandoutNobel
Role of the Akt pathway in mRNA translation of interferon-stimulated genes
2008
Works of Yazan Alsayed being referenced
Activation of Rac1 and the p38 Mitogen-activated Protein Kinase Pathway in Response to All-trans-retinoic Acid
2001
TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3
2009
Activation of the p38 Mitogen-activated Protein Kinase by Type I Interferons
1999
Interaction of p59fynwith Interferon-Activated Jak Kinases
1997
CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors
1999
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3
2007
The Type I Interferon Receptor Mediates Tyrosine Phosphorylation of the CrkL Adaptor Protein
1997
Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma
2008
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease
2008
High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2
2010
Anatomic and functional imaging in the management of lymphoma.
2007
Superior results of Total Therapy 3 (2003-33) in gene expression profiling–defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance
2010
Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment
2008
Interferon-α Resistance in a Cutaneous T-Cell Lymphoma Cell Line Is Associated With Lack of STAT1 Expression
1998
Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival
2009
Integration of DNA Copy Number and Gene Expression Alterations Reveal Novel Insights into the Molecular Pathogenesis and Prognosis of Multiple Myeloma
2008
Interferon-α Resistance in a Cutaneous T-Cell Lymphoma Cell Line Is Associated With Lack of STAT1 Expression
1998
Combination Mammalian Target of Rapamycin Inhibitor Rapamycin and HSP90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin Has Synergistic Activity in Multiple Myeloma
2006
IFN-γ Activates the C3G/Rap1 Signaling Pathway
2000
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
2008
Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols
2009